NIOX Group (LON:NIOX) Shares Down 1% – Time to Sell?

NIOX Group Plc (LON:NIOX) shares dropped 1% on Monday . The stock traded as low as GBX 56.48 and last traded at GBX 57. 575,719 shares were traded during trading, a decline of 32% from the average daily volume of 845,308 shares. The stock had previously closed at GBX 57.60.

NIOX Group Price Performance

The business’s 50 day moving average is GBX 60.52 and its two-hundred day moving average is GBX 63.17. The firm has a market cap of £239.89 million, a P/E ratio of 34.76 and a beta of 0.92. The company has a quick ratio of 1.94, a current ratio of 3.81 and a debt-to-equity ratio of 1.36.

NIOX Group (LON:NIOX) last released its earnings results on Tuesday, March 24th. The company reported GBX 4.03 earnings per share (EPS) for the quarter. NIOX Group had a net margin of 14.37% and a return on equity of 10.14%. As a group, analysts anticipate that NIOX Group Plc will post 1.1658256 earnings per share for the current year.

Insider Activity

In other news, insider Sarah Duncan sold 164,612 shares of the business’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of GBX 56, for a total value of £92,182.72. Also, insider Jonathan Emms sold 325,273 shares of the company’s stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of GBX 56, for a total value of £182,152.88. Over the last three months, insiders bought 102,805 shares of company stock valued at $5,996,817 and sold 662,056 shares valued at $37,453,394. Company insiders own 5.11% of the company’s stock.

NIOX Group Company Profile

NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings.

Headquartered in the UK and listed on the London Stock Exchange (ticker: NIOX), the company operates internationally, serving healthcare professionals in over 50 countries.